A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

Sponsor
GlaxoSmithKline
Study ID
NCT07456033
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Depemokimab — DRUG
    Depemokimab will be administered
  • Placebo — DRUG
    Placebo will be administered

Study Details

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Key Dates

Start date
Mar 6, 2026
Status verified
Mar 2026
Primary completion
Jul 1, 2030
Completion
Jul 1, 2030

Study Design

Enrollment
456 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Depemokimab
    Participants will be administered depemokimab along with standard of care (SoC).
  • Placebo Comparator: Placebo
    Participants will be administered placebo along with SoC

Primary Outcome Measure

Annualized rate of clinically significant exacerbations [ Time Frame: Up to Week 156 ]

Central Contacts

Related Studies